AnalystBook Research · Company Intelligence

CLARIVATE PLC

CLVTNYSE

Built from CLARIVATE PLC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Clarivate narrowed its loss and lifted FCF, but revenue declined.

The read at a glance✓ Audited against SEC data
  • Business mixResearch and IP intelligenceNote
  • Revenue$2.46B, -4.0%Watch
  • Net loss($201.1M), narrowerOK
  • FCF$365.3M, +2.2%OK
  • Debt$4.32B, -4.4%OK
  • Altman/Beneish/EQWeak Z; clean M/EQWatch
  • Insiders5 purchases / 1 saleOK

Business

Clarivate provides intelligence, workflow software, and tech-enabled services across Academia and Government, Intellectual Property, and Life Sciences and Healthcare.

Where the revenue comes from

Fiscal 2025, as CLARIVATE PLC reports it. History and quarterly detail are in the app.

  • A&G$1.3B

Leadership changes

From CLARIVATE PLC's own filings, the day they're filed.

  • Valeria Alberola · Directors · departureeff. 2025-12-31
  • Intellectual Property Gordon Samson · President · departureeff. 2025-09-07
  • Richard Roedel · Directors · departureeff. 2024-12-31

Latest filings

  • 8-K · Company announcement2026-07-29
  • 10-Q · Quarterly report2026-07-29
  • 8-K · Company announcement2026-07-29
  • 8-K · Company announcement2026-07-06
  • 8-K · Company announcement2026-07-06
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about CLARIVATE PLC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.